Li Li's public explanation of the "only Theory"

The market to the Hepalink as a flood of questioning, and finally let the hidden in the spotlight of the chairman of the Sea, Mr. Li Lithium no longer gan "silent Lamb." Yesterday morning, Li Li with Dong Bu Haihua, sponsor representative of the securities Wang Tao, Hepalink, the United States Drug Administration agent of the United States Drug Company (hereinafter referred to as DSC) executives, in Shenzhen, held a company since the IPO of the first public exchange.　　But in addition to spending nearly a half of its time explaining the Hepalink of FDA certification, many of the core issues have been overlooked again, and the avoidance and branching of the topic seems to be the only way Li has been in the exchange. insisted that the FDA certification is the only yesterday 9:30 A.M., Shenzhen Marco Good Day Hotel, in public waiting for Li Lithium line of people to come, hepalink sharply lower open early market followed. Hepalink not for the IPO since the first public exchange suspension, which inevitably makes people wonder: is the Exchange is a drama?　　Hepalink was planning on not disclosing important information? The 148-dollar issue gave investors an instant memory of three nouns: hepalink, heparin sodium, and the FDA (Food and Drug Administration). "Only one by one of our national FDA-certified Heparin Sodium API Production Enterprises"-and then the controversy is around here.　　Domestic counterparts, medical experts, association leaders and even the FDA spokesman testified: Hepalink "The only Theory" for fiction. But Hepalink still seems unmoved.　　At the conference, DSC senior Vice President, Drug Administration expert David spent nearly half of the time to explain the FDA certification issues, once again give Hepalink a shot of the tonic. As previously stated in the bulletin, the FDA certification process, which includes the seven major steps of site registration and product registration, was hepalink by David as evidence of Hepalink's "Only Theory": Completion of site registration from March 18, 2003, FDA approval by May 27, 2005　　, Hepalink time consuming more than two years, is the domestic only one by one to walk through the FDA's complete certification procedures and hold the FDA Drug Evaluation and Research Center approved the letter of the heparin sodium raw materials production enterprises. The domestic counterparts who have questioned the Prive of the sea seem to have died down. Yesterday, the reporter tried to the above comments on the sea, Yantai Dongcheng, Changzhou thousand red head, were rejected. Xu Kangsheng, the Secretary general of the Chinese Biochemical Pharmaceutical Association, who had previously judged that he was "less realistic", was unable to say clearly and not when he talked about the breakdown of heparin raw materials and heparin APIs yesterday.　　Yesterday, the reporter also interviewed the National Drug Administration spokesman Jiangying, said the other side, the domestic drug companies should obtain FDA certification, do not need to report information in the country, so at present, the FDA also has no statistical information to confirm the "only theory". Hepalink's explanation of "The only theory" will stop there, but what about the competitors on the market? Even now the domestic market is still a solo show, but the peers in the FDA certification will eat away the Hepalink market share? "Our confidence comes from product quality andWith this high quality technology, we have the confidence to dominate the market.　　Speaking of products, the silent Li Li finally spoke. Cut the continuous Chongqing Tongda in Li Lithium entrepreneurial process, Chongqing Tongda is not to erase a pen. 1998, Li Lithium in Chongqing with access to the end of the production of heparin sodium hepalink, and then through a number of equity transfer, 2000, Li Lithium Holdings of the music industry to become the largest shareholder in Chongqing, since then, Chongqing Tongda no longer engaged in the production and operation of heparin sodium. 2003, Chongqing Tongda will produce heparin sodium drug approval number to change to the sea of Puri.　　Chongqing Tongda, which has been discontinued since then, was written off in 2008. Seemingly smooth process is full of doubt: since heparin sodium in the market is completely competitive today have such a good prospect, then in the competition is not fierce at the end of the century, the background of the state-owned enterprises in Chongqing Why the transfer of equity to private enterprises? What is the price of the transfer? And why Li Li in Chongqing after the hand and let it idle?　　Why was it written off at the beginning of the listing of the company? In a conversation with a medical expert, the journalist seems to have found a little answer. BEIJING, a state-owned drug companies, the Director of Research and Development Center told reporters that around 2000, private enterprises to apply for a drug approval document number of obstacles, and the relevant laws and regulations allow the group of different enterprises in the same variety of drug approval number transfer. It is not difficult to know, Li Lithium acquisition of Chongqing Tongda is not source.　　And it is true that Hepalink's existing drug approval number for the production of Heparin sodium API was transferred from Chongqing. Yesterday, when the reporter mentioned Chongqing Tongda, Li Lithium seems to be a little insincere: "I have not in the history of direct acquisition of private enterprise shares." The answer is dubious. According to the prospectus, during Li Li's tenure as chairman of Chongqing Tongda, a company called Haihua Trading, through two equity transfers in 1995 and 1997, will release Chongqing Tongda 60% of the state-owned corporate shares completely. In August 1998, Hepalink first appeared in Chongqing Tongda's shareholder list, the transfer founder is the sea-China trade.　　Finally after the transfer, to July 2000, the Sea-China trade owned Chongqing Tongda 60% stake in the name of the lottery to Li Li. Ultra-raised funds will be used to finance the main business listing despite the doubts, it is true that the IPO is making a full profit.　　So, how Hepalink will be at the mercy of up to 5 billion yuan of super raise money?　　Hepalink Dong Haihua said yesterday that the company's plan to raise funds is based on the 2007 market to budget, and now heparin sodium raw material prices have risen sharply, so the super raise funds will be used to expand the heparin sodium raw material medicine main industry.　　On the issue of raw material supply after the expansion of the company's capacity, Li Li said that the domestic heparin coarse products can meet the needs of the expansion of the company, the company will not be diverted to other products in the near future production. In addition, Goldman Sachs, the third-largest shareholder in Hepalink, has made its rounds in the IPO. Even now that Hepalink has been break, its more than 6 billion-dollar market capitalisation has already made Goldman'sThe second Western mining industry. 2008, Goldman Sachs spent 200 million or 300 million yuan in Hunan, Fujian area to acquire more than 10 pig farms, set off a burst of domestic pig fever. Now, is Goldman's pig-raising program part of the Hepalink strategy?　　In addition to equity investment, Hepalink and Goldman Sachs have other cooperation? "The entry of Goldman Sachs has brought a global perspective on the company's strategic development", and Li Lithium seems to be grateful to the most influential shareholder. But he did not answer the reporters ' questions, saying only that Goldman Sachs, in the US market, had proactively discovered the up-and-coming, and then became a shareholder at Highbury.　　Avoiding and branching the subject seems to be the only way Li Lithium is in the exchange. Newspaper reporter Miaohui